(ABT; Aa3/AA-/NR)
• $21bn acquisition closing 2Q 26. $23bn when Exact's debt is included.
• Exact Sciences has $3bn revenue growing high teens organically. Expected to earn $630m EBITDA in 2026.
• More from US analyst later.
Find more articles and bullets on these widgets:
Full Article: US DAILY BRIEF